Streptokinase is one of the most commonly used thrombolytic agents for the treatment of
thromboembolism. Short half-life of the streptokinase requires administration of higher dose …

In recent times, search for potent and highly selective thrombolytic agents with minimal side
effects has become a major area of research. The aim of the present study was to develop …

Streptokinase is an efficient thrombolytic agent used to treat thromboembolic disorders.
Conventional streptokinase formulations have limited thrombolytic activity and several …

The use of streptokinase (SK) in the clinic is limited by the lack of fibrin-specificity and the
short half-life of the drug. We have developed a new dosage form of streptokinase …

Vascular diseases leading to thrombo-occlusion are the leading cause of morbidity and
mortality worldwide. Revascularization and restoration of antegrade blood flow is critical for …

The present study was aimed to study the effect of RGD peptide conjugation on the bio-
distribution behaviour of long circulatory liposomes in the thrombosed rat model. Further …

To prolong the biological half-life of streptokinase, a thrombolytic agent, streptokinase-
bearing liposome with and distearolyphosphatidyl ethanolamine-N-poly (ethylene glycol) …

Several plasminogen activators (PAs) have been found effective in treating different
thromboembolic diseases. However, administration of conventional thrombolytic therapy is …

AIM: To prepare thrombus-targeted urokinase liposomes and observe its improved
thrombolytic efficacy on thrombus model rats. METHODS: The ligand H-Arg-Gly-Asp-Ser-OH …

The successful design of new thrombolytic agents depends on providing these agents with
increased clot selectivity. As recently demonstrated (10), entrapment of tissue plasminogen …